Gene therapy and genetic engineering are transforming the landscape of personalized and regenerative medicine by offering precise, targeted corrections at the genetic level. These technologies enable the replacement, repair, or regulation of defective genes using viral or non-viral delivery systems, significantly altering the course of inherited and acquired diseases. In tissue engineering, gene editing plays a pivotal role in programming stem cells, enhancing scaffold-cell interactions, and boosting tissue regeneration. Breakthroughs such as CRISPR-Cas9, base editing, and prime editing allow high-fidelity genomic modifications, minimizing off-target effects and increasing clinical feasibility. Gene therapy and genetic engineering are also being integrated into smart biomaterial systems and synthetic biology platforms to provide controlled release and spatially defined gene expression. As regulatory frameworks adapt, more gene-modified cell and tissue products are entering early-stage trials, suggesting a shift toward curative and adaptive solutions for complex diseases.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy